BioSpace News Archive

bluebird bio, Inc. announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights.

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, reported financial results for the second quarter ended June 30, 2021.

Merrimack Pharmaceuticals, Inc. announced its second quarter 2021 financial results for the period ended June 30, 2021.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for genetic diseases, today announced results for the three-month and first six-month periods ending June 30, 2021.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced financial results for the second quarter ended June 30, 2021 and reviewed recent corporate updates.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the second quarter ended June 30, 2021.

Progenity, Inc., an innovative biotechnology company, announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets.

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2021.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2021 financial results and provided a business update.